Press Releases

BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14

NEW YORK and PETACH TIKVAH, Israel, May 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015 financial results on Thursday, May 14, 2015.  The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. Eastern Time to discuss the results.

Conference Call & Webcast

Thursday, May 14, 2015 at 8:30 a.m. ET/5:30 a.m. PT
   Domestic:                            888-299-7209
   International:                        719-325-2244
   Conference ID:                     9028301


Available through May 28, 2015
   Domestic:                              877-870-5176
   International:                          858-384-5517
   Conference ID:                       9028301

BrainStorm Cell Therapeutics

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at

Logo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media: Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460,; or Investors: Michael Wood, LifeSci Advisors, LLC, 646-597-6983,
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds